Abiopharma

🔍 Booth Bruce (Executive)

Company: Kymera Therapeutics, Inc. (KYMR)

Report Date: 2025-12-10

Detailed Transactions and Holdings:

• Sold 31,459 shares of Common Stock at $88.64 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,141,757.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 17,825 shares of Common Stock at $89.25 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,123,932.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 10,545 shares of Common Stock at $90.14 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,113,387.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 47,349 shares of Common Stock at $92.41 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,066,038.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 85,862 shares of Common Stock at $93.2 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,980,176.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 5,979 shares of Common Stock at $88.64 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 717,267.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 3,391 shares of Common Stock at $89.25 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 713,876.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 2,001 shares of Common Stock at $90.14 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 711,875.00 | transaction_form_type: 4 | Footnotes: F4, F7
• Sold 9,060 shares of Common Stock at $92.41 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 702,815.00 | transaction_form_type: 4 | Footnotes: F5, F7
• Sold 16,338 shares of Common Stock at $93.2 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 686,477.00 | transaction_form_type: 4 | Footnotes: F6, F7
• Sold 5,125 shares of Common Stock at $91.23 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,975,051.00 | transaction_form_type: 4 | Footnotes: F8, F2
• Sold 976 shares of Common Stock at $91.23 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 685,501.00 | transaction_form_type: 4 | Footnotes: F8, F7
• Sold 570 shares of Common Stock at $91.04 per share (Direct)
  Date: 2025-12-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,974,481.00 | transaction_form_type: 4 | Footnotes: F9, F2
• Sold 108 shares of Common Stock at $91.04 per share (Direct)
  Date: 2025-12-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 685,393.00 | transaction_form_type: 4 | Footnotes: F9, F7

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (8) and (9).
• F2: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.71 inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.55 inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.9969 inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.6935 inclusive.
• F7: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.54 inclusive.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.33 inclusive.